Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BLFS advanced for three days, in 235 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The 10-day RSI Indicator for BLFS moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 21 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BLFS as a result. In 93 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for BLFS turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 45 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLFS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
BLFS broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BLFS entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. BLFS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 56 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.560) is normal, around the industry mean (5.011). P/E Ratio (39.140) is within average values for comparable stocks, (163.451). BLFS's Projected Growth (PEG Ratio) (15.094) is slightly higher than the industry average of (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (16.779) is also within normal values, averaging (56.074).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The Aroon Indicator for RGEN entered a downward trend on September 21, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 211 similar instances where the Aroon Indicator formed such a pattern. In 173 of the 211 cases the stock moved lower. This puts the odds of a downward move at 82%.
The 10-day RSI Indicator for RGEN moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 20 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGEN as a result. In 66 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 42 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 69 cases where RGEN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
RGEN moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 227 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.187) is normal, around the industry mean (5.011). P/E Ratio (265.877) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
BLFS | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 47 | 76 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 56 | 88 | |
PRICE GROWTH RATING 1..100 | 36 | 39 | |
P/E GROWTH RATING 1..100 | 29 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RGEN's Valuation (86) in the Biotechnology industry is in the same range as BLFS (98) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to BLFS’s over the last 12 months.
RGEN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BLFS (100) in the Medical Specialties industry. This means that RGEN’s stock grew similarly to BLFS’s over the last 12 months.
BLFS's SMR Rating (56) in the Medical Specialties industry is in the same range as RGEN (88) in the Biotechnology industry. This means that BLFS’s stock grew similarly to RGEN’s over the last 12 months.
BLFS's Price Growth Rating (36) in the Medical Specialties industry is in the same range as RGEN (39) in the Biotechnology industry. This means that BLFS’s stock grew similarly to RGEN’s over the last 12 months.
BLFS's P/E Growth Rating (29) in the Medical Specialties industry is significantly better than the same rating for RGEN (100) in the Biotechnology industry. This means that BLFS’s stock grew significantly faster than RGEN’s over the last 12 months.
| BLFS | RGEN | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 72% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 72% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 73% |
| Advances ODDS (%) | 11 days ago 77% | 2 days ago 73% |
| Declines ODDS (%) | 15 days ago 83% | 8 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BLFS’s FA Score shows that 1 FA rating(s) are green while RGEN’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BLFS’s TA Score shows that 1 TA indicator(s) are bullish while RGEN’s TA Score has 4 bullish TA indicator(s).
BLFS (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while RGEN (@Pharmaceuticals: Other) price change was +6.57% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.85%. For the same industry, the average monthly price growth was -3.07%, and the average quarterly price growth was +5.51%.
BLFS is expected to report earnings on Nov 05, 2026.
RGEN is expected to report earnings on Oct 27, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| BNX.X | 34.055832 | -0.105984 | -0.31% |
| BinaryX [Old] cryptocurrency | |||
| MDT.X | 0.006765 | -0.000082 | -1.20% |
| Measurable Data Token cryptocurrency | |||
| NEXO.X | 0.812743 | -0.016712 | -2.01% |
| Nexo cryptocurrency | |||
| PIXEL.X | 0.005781 | -0.000228 | -3.80% |
| Pixels cryptocurrency | |||
| AMP.X | 0.000670 | -0.000084 | -11.11% |
| Amp cryptocurrency | |||